Dorsolateral Versus Medial Prefrontal TMS for Depression
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- White River Junction Veterans Affairs Medical Center
- Locations
- 1
- Primary Endpoint
- Depressive symptoms measured by the 17-item Hamilton Depression Rating Scale
- Status
- Withdrawn
- Last Updated
- 4 years ago
Overview
Brief Summary
This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation at the forehead versus the left side of the head for treatment of Treatment Resistant Depression.
Detailed Description
While transcranial magnetic stimulation (TMS) to the left dorsolateral prefrontal cortex (DLPFC) is an FDA approved treatment for depression, a growing and converging database suggests the medial prefrontal cortex (MPFC) may be even more critical to the neurobiology of depression and antidepressant treatment response. This study will compare the efficacy of high frequency transcranial madntic stimulation on these two sections of the brain.
Investigators
Paul Holtzheimer
Director of Mood Disorder Services
White River Junction Veterans Affairs Medical Center
Eligibility Criteria
Inclusion Criteria
- •21-70 years old
- •inadequate response to one current antidepressant medication
- •currently depressed
Exclusion Criteria
- •psychiatric comorbidities
Outcomes
Primary Outcomes
Depressive symptoms measured by the 17-item Hamilton Depression Rating Scale
Time Frame: Change from baseline Hamilton-17 score to follow-up visit at 1 week after final TMS intervention.
Depressive symptoms will be measured by the 17-item Hamilton Depression Rating Scale.